ATE175446T1 - Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung - Google Patents
Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindungInfo
- Publication number
- ATE175446T1 ATE175446T1 AT91911895T AT91911895T ATE175446T1 AT E175446 T1 ATE175446 T1 AT E175446T1 AT 91911895 T AT91911895 T AT 91911895T AT 91911895 T AT91911895 T AT 91911895T AT E175446 T1 ATE175446 T1 AT E175446T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- connection
- immunogenic peptides
- receptor binding
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52463290A | 1990-05-16 | 1990-05-16 | |
| US66907291A | 1991-03-14 | 1991-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE175446T1 true ATE175446T1 (de) | 1999-01-15 |
Family
ID=27061560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91911895T ATE175446T1 (de) | 1990-05-16 | 1991-05-16 | Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US5817316A (de) |
| EP (1) | EP0651818B1 (de) |
| JP (1) | JPH05507491A (de) |
| AT (1) | ATE175446T1 (de) |
| CA (1) | CA2082948C (de) |
| DE (1) | DE69130741T2 (de) |
| WO (1) | WO1991017764A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992007878A1 (en) * | 1990-10-26 | 1992-05-14 | The Public Health Research Institute Of The City Of New York, Inc. | Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120 |
| JPH05262662A (ja) * | 1991-07-15 | 1993-10-12 | Calpis Food Ind Co Ltd:The | Hiv重感染防止剤、抗イディオタイプ抗体作製用抗原及び抗イディオタイプ抗体の製造法 |
| US5665569A (en) * | 1991-08-22 | 1997-09-09 | Nissin Shokuhin Kabushiki Kaisha | HIV immunotherapeutics |
| EP0581353A1 (de) * | 1992-07-03 | 1994-02-02 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Monoklonale Antikörper gegen HIV-1 gp120, Zellinien die sie herstellen und entsprechende Epitope-Strukturen |
| US6193982B1 (en) | 1995-04-27 | 2001-02-27 | The United States Of America As Represented By The Department Of Health & Human Services | Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120 |
| US6428790B1 (en) | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| US6780847B2 (en) | 1995-04-27 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
| US6987096B1 (en) | 1995-04-27 | 2006-01-17 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof |
| US5843882A (en) | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
| US7048935B2 (en) | 1995-04-27 | 2006-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| US6908617B1 (en) | 1997-11-10 | 2005-06-21 | Dana-Farber Cancer Institute, Inc. | Glycosylated modified primate lentivirus envelope polypeptides |
| US7048929B1 (en) | 1997-11-10 | 2006-05-23 | Dana-Farber Cancer Institute, Inc. | Stabilized primate lentivirus envelope glycoproteins |
| US6679851B2 (en) * | 1998-09-01 | 2004-01-20 | Senorx, Inc. | Tissue accessing and anchoring device and method |
| US7585839B2 (en) * | 2000-02-23 | 2009-09-08 | Zealand Pharma A/S | Medical uses of intercellular communication facilitating compounds |
| US7250397B2 (en) * | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
| AU2001254567A1 (en) * | 2000-05-02 | 2001-11-12 | Simon Fraser University | Polypeptides for use as a vaccine and/or treatment for hiv infection |
| CA2431212A1 (en) * | 2000-12-27 | 2002-07-25 | Richard T. Wyatt | Immunogenic proteoliposomes, and uses thereof |
| DE60221705T2 (de) | 2001-03-22 | 2008-06-05 | The United States of America, represented by the Secretary, Dept. of Health and Human Services, the Natl. Institutes of Health, Office of Technology Transfer | Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine |
| JP2006504435A (ja) * | 2002-05-10 | 2006-02-09 | ザ ヘンリー エム. ジャクソン ファウンデイション | HIV−1のgp120のgp41への相互作用部位 |
| JP3849584B2 (ja) * | 2002-06-07 | 2006-11-22 | トヨタ自動車株式会社 | 蒸発燃料処理装置 |
| MXPA05013334A (es) * | 2003-06-12 | 2006-05-19 | Vexgen Inc | Glucoproteinas de envoltura de vih-1 que tienen estructuras de disulfuro inusuales. |
| CA2539452C (en) * | 2003-09-17 | 2013-10-29 | Guava Technologies, Inc. | Compositions and methods for analysis of target analytes |
| CA2637600A1 (en) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Heteroduplex tracking assay |
| US20100298225A1 (en) * | 2007-07-15 | 2010-11-25 | Bjarne Due Larsen | Peptide gap junction modulators |
| CN107149679B (zh) * | 2009-03-05 | 2021-03-02 | 哈佛学院董事会 | 分泌的aP2及其抑制方法 |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| EP2492279A1 (de) * | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| AU2012279018B2 (en) | 2011-07-05 | 2017-06-08 | Children's Medical Center Corporation | N-terminal deleted GP120 immunogens |
| CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| WO2013052095A2 (en) | 2011-10-03 | 2013-04-11 | Duke University | Vaccine |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| EP2848937A1 (de) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Verfahren zur Identifizierung neuartiger HIV-1-Immunogene |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| TW201702271A (zh) | 2015-04-30 | 2017-01-16 | 哈佛大學校長及研究員協會 | 治療代謝病症之抗-ap2抗體及抗原結合劑 |
| WO2018227200A1 (en) | 2017-06-09 | 2018-12-13 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
| JP7641223B2 (ja) * | 2019-01-28 | 2025-03-06 | サイフォス、バイオサイエンシズ、インコーポレイテッド | Car細胞上の非天然nkg2d受容体に、結合した異種分子を選択的に送達する改変非天然nkg2dリガンド |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0279688B1 (de) * | 1987-02-20 | 1997-04-16 | Genentech, Inc. | Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern |
| US5109123A (en) * | 1988-06-14 | 1992-04-28 | Dana Farber Cancer Institute | Alteration of ability of soluble CD4 fragments to bind HIV |
-
1991
- 1991-05-16 EP EP91911895A patent/EP0651818B1/de not_active Expired - Lifetime
- 1991-05-16 WO PCT/US1991/003472 patent/WO1991017764A1/en not_active Ceased
- 1991-05-16 CA CA002082948A patent/CA2082948C/en not_active Expired - Fee Related
- 1991-05-16 AT AT91911895T patent/ATE175446T1/de not_active IP Right Cessation
- 1991-05-16 JP JP91511185A patent/JPH05507491A/ja active Pending
- 1991-05-16 DE DE69130741T patent/DE69130741T2/de not_active Expired - Fee Related
-
1992
- 1992-03-26 US US07/858,165 patent/US5817316A/en not_active Expired - Fee Related
-
1993
- 1993-10-12 US US08/135,312 patent/US5858366A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0651818A1 (de) | 1995-05-10 |
| DE69130741D1 (de) | 1999-02-18 |
| WO1991017764A1 (en) | 1991-11-28 |
| CA2082948C (en) | 2000-07-11 |
| JPH05507491A (ja) | 1993-10-28 |
| EP0651818A4 (de) | 1993-08-09 |
| US5817316A (en) | 1998-10-06 |
| DE69130741T2 (de) | 1999-07-29 |
| EP0651818B1 (de) | 1999-01-07 |
| US5858366A (en) | 1999-01-12 |
| CA2082948A1 (en) | 1991-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE175446T1 (de) | Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung | |
| DE69939327D1 (de) | Funktionelle antagonisten von hedgehog-aktivität | |
| DE69406423D1 (de) | Methode zum überbringen von agenzien an zielzellen | |
| NO891711L (no) | Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr. | |
| ATE112687T1 (de) | Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen. | |
| CZ105795A3 (en) | Pharmaceutical preparation containing antagonists of vascular endothelial cell growth factor | |
| CA2290485A1 (en) | Method for the production of non-immunogenic proteins | |
| DE3588254D1 (de) | Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen | |
| AU1986588A (en) | Growth hormone receptor | |
| DE69632815D1 (de) | gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER | |
| NO980293L (no) | Fremgangsmåte til fremstilling av et polypeptid | |
| FR2669338B1 (de) | ||
| IL127595A (en) | Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use | |
| EP0284587A3 (de) | Synthetische Peptid-Antigene für den Nachweis von HIV-1-Infektionen | |
| TR199800912T2 (xx) | T�m�r a��s� ve a��n�n haz�rlanmas� i�in usul. | |
| ATE238065T1 (de) | Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus | |
| EP0344006A3 (de) | Peptide, welche die Bindung von HIV-1 zum CD4-Rezeptor-Protein blockieren | |
| NZ333203A (en) | Tumour antigen proteins, genes thereof, and tumour antigen peptides | |
| DE69535855D1 (de) | Calciumbindende rekombinante antikörper gegen protein c | |
| AU4712993A (en) | New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods | |
| IL150045A0 (en) | Compositions and methods for detecting stress-inducible proteins | |
| ES2009280A6 (es) | Un metodo para detectar anticuerpos al virus hiv-1 en una muestra. | |
| NO923415L (no) | Forbedrede chimere toksiner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |